TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34036177
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) treatment for 4 weeks
Study: 34037715
Drug: Ustekinumab 130
Normalized name: ustekinumab 130 MG in 26 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 130 mg (≥40 kg) or 3 mg/kg (<40 kg)
Study: 34037715
Drug: Ustekinumab 390
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 390 mg (≥40 kg) or 9 mg/kg (<40 kg)
Study: 34038379
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg 4 times daily for 1 year
Study: 34038379
Drug: Domperidone treatment
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone treatment
Study: 34039285
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of plasma uric acid (PUA) (373 µmol/l)
Study: 34039285
Drug: Lowest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quartile of plasma uric acid (PUA) (234 µmol/l)
Study: 34039438
Drug: Blended therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended therapy (interactive tablet-based home exercise program combined with face-to-face therapy sessions)
Study: 34039905
Drug: Guided self-rehabilitation
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-rehabilitation contracts (GSCs) combined with abobotulinumtoxinA injections (1500 U)
Study: 34040174
Drug: Berzosertib (90-210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berzosertib (90-210 mg) plus cisplatin (day 1) every 3 weeks (Q3W)
Study: 35245205
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (GHT)
Study: 34040400
Drug: Ibuprofen (600-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600-800 mg three times daily)
Study: 34040605
Drug: Intracerebral gene
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracerebral gene therapy with recombinant AAV serotype 2/5 (rAAV2/5) coding human NAGLU
Study: 34041648
Drug: Micro-fluid challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-fluid challenge (50 ml crystalloid infused in 10 seconds)
Study: 34041706
Drug: Telavancin (750.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin (750.0 mg or 8.2 mg/kg) administered for a median of 26 days (IQR, 12, 42 days)
Study: 34042098
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg subcutaneously (60 mg in obese patients, 20 mg in renal failure)
Study: 34043812
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg daily)
Study: 34043894
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (30 μg, two injections, 21 days apart)
Study: 34045234
Drug: M3258, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: M3258, an orally bioavailable, potent, reversible and highly selective LMP7 inhibitor
Study: 34045689
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention including one boiled egg and 150 ml milk daily 6 days a week for 3 months; psychosocial stimulation including structured play activities and parental counseling for 6 months; routine clinical care.
Study: 34046035
Drug: UV1 vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV1 vaccination with GM-CSF as an adjuvant in combination with ipilimumab
Study: 34046915
Drug: Capmatinib 200
Normalized name: capmatinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capmatinib 200 mg (single oral dose)
Study: 34047178
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide and all-trans retinoic acid treatment
Study: 34047959
Drug: Dulaglutide (once-weekly)
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dulaglutide (once-weekly)
Study: 34048282
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with Ifetroban, a potent and selective thromboxane A2 receptor antagonist.
Study: 34048509
Drug: Activity monitor
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity monitor (AM) with personalized daily step goal and resistance exercises
Study: 34048594
Drug: peginterferon therapy
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon therapy for more than 6 months
Study: 34048681
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance at 10 mg for 21 days of 28-day cycles until progression or unacceptable toxic effects for up to 5 years.
Study: 34048794
Drug: Event-driven PrEP
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Event-driven PrEP (2+1+1 dosing)
Study: 34048794
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral PrEP (tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg)
Study: 34049394
Drug: Adjustment for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustment for dietary lutein (L) and zeaxanthin (Z) intake
Study: 34050027
Drug: Liposome-displayed trimeric
Normalized name: glyoxal trimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome-displayed trimeric H3 HA vaccine; dosage: as low as 2 ng HA; duration: not specified.
Study: 34050027
Drug: Passive serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive serum transfer from immunized mice; dosage: not specified; duration: not specified.
Study: 34050027
Drug: Immunization with
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization with liposome system containing 10 recombinant surface antigens; dosage: 5 ng individual antigen; duration: not specified.
Study: 34050027
Drug: Immunization in
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization in ferrets; dosage: not specified; duration: not specified.
Study: 34050260
Drug: Isatuximab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatuximab (10 mg/kg weekly for 4 weeks, then every other week) with pomalidomide and dexamethasone (Pd)
Study: 34051329
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg intravenously every 2 weeks until unacceptable toxicity or disease progression
Study: 34051732
Drug: Non-ipilimumab therapy
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Non-ipilimumab therapy
Study: 34051732
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg) and Non-ipilimumab therapy
Study: 34052705
Drug: Binimetinib 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib 30 mg BID (DL1)
Study: 34052705
Drug: Binimetinib 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib 45 mg BID (DL2)
Study: 34053700
Drug: Capmatinib 300
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 300 mg BID with food
Study: 34053700
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg BID with food
Study: 34054569
Drug: sildenafil (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: sildenafil (specific phosphodiesterase-5 inhibitor)
Study: 34055086
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of paclitaxel (70 mg/m2) with modulated electro-hyperthermia
Study: 34055086
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of cisplatin with modulated electro-hyperthermia
Study: 34055403
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group with SBP target of <120 mm Hg
Study: 34055403
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group with SBP target of <140 mm Hg
Study: 34055928
Drug: Preexisting Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preexisting Oral Anticoagulant Therapy
Study: 34056607
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg Q2W until disease progression, unacceptable toxicity, or trial withdrawal
Study: 34056607
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg Q2W
Study: 34056870
Drug: Surgical debridement,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical debridement, antibiotic, and hyperbaric oxygen therapy over a 6-month period
Study: 34056892
Drug: iVascular Luminor™
Approvals — FDA: no, EMA: no, PMDA: no
Description: iVascular Luminor™ drug-coated balloon (DCB) and Angiolite™ drug-eluting stent
Study: 34057424
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for 16 weeks
Study: 34058027
Drug: Mirabegron (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (25 mg, increased to 50 mg if tolerated)
Study: 34059026
Drug: Aldosterone to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone to renin ratio (ARR) > 10 (ng/dL)/(mU/L) after confirmatory test
Study: 34059991
Drug: Tenofovir Alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir Alafenamide (TAF), median duration of dosing 74 weeks
Study: 34060012
Drug: NTK 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTK 120 mg once every 2 weeks (NTK Q2W)
Study: 34060012
Drug: NTK 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTK 120 mg once every 4 weeks (NTK Q4W)
Study: 34060440
Drug: Ophthalmic grader
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ophthalmic grader pathway
Study: 34060440
Drug: Ophthalmic grader
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ophthalmic grader pathway (seven-field Early Treatment Diabetic Retinopathy Study)
Study: 34060440
Drug: Ophthalmic grader
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ophthalmic grader pathway (ultra-wide field imaging)
Study: 34060483
Drug: Systemic pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic pharmacological blockade of activin A using soluble activin receptor type IIB ligand trap
Study: 34060483
Drug: Muscle-specific adeno-associated
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle-specific adeno-associated virus-mediated downregulation of its receptor ACVR2A/B
Study: 34060704
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation discontinuation (≥7 consecutive days)
Study: 34060714
Drug: Non-selective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective beta-blockers (NSBB) administered intravenously
Study: 34064209
Drug: Chiropractic spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic spinal adjustments combined with physical therapy (chiro + PT)
Study: 34064209
Drug: Sham chiropractic
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham chiropractic with physical therapy (sham + PT)
Study: 34065517
Drug: Integrative Psychotherapeutic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative Psychotherapeutic Group Treatment (IPGT)
Study: 34065859
Drug: Venetoclax/S63845 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax/S63845 combination therapy
Study: 34067093
Drug: Uncoupling protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoupling protein 1 (UCP1), specific dosage and duration not mentioned
Study: 34070172
Drug: Fludarabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine plus low-dose cytarabine (FLUGA)
Study: 34070561
Drug: Oxaliplatin (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin (starting dose 100 mg/sm, maximum 300 mg/sm)
Study: 34070561
Drug: Cisplatin (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (starting dose 15 mg/sm)
Study: 34070561
Drug: Doxorubicin (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (starting dose 3 mg/sm)
Study: 34070561
Drug: PIPAC (Pressurized
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPAC (Pressurized Intra-Peritoneal Aerosol Chemotherapy)
Study: 34071188
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) as first-line therapy for HCC
Study: 34071188
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor (CAR)-engineered NK cells and T cells
Study: 34071908
Drug: Opioid maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid maintenance therapy
Study: 34074856
Drug: HBO2 (Hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO2 (Hyperbaric Oxygen Therapy) within 6 hours
Study: 34074889
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (e.g., dapagliflozin)
Study: 34076556
Drug: MenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenB vaccine
Study: 34076831
Drug: Continuation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation group (tandem high-dose chemotherapy (HDCT) and craniospinal irradiation (CSI))
Study: 34076831
Drug: Switched group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched group (modified treatment)
Study: 34078022
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg for 24 weeks, increased to 40 mg if necessary after 12 weeks
Study: 34078260
Drug: D-chiro-inositol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-chiro-inositol (1 g/day) for 1 month
Study: 34078435
Drug: S100B >
Approvals — FDA: no, EMA: no, PMDA: no
Description: S100B > 0.10 μg/L
Study: 34078435
Drug: S100B <
Approvals — FDA: no, EMA: no, PMDA: no
Description: S100B < 0.10 μg/L
Study: 34078651
Drug: FP-1305 (bexmarilimab),
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP-1305 (bexmarilimab), a humanized IgG4 anti-Clever-1 antibody
Study: 34079488
Drug: Flexibly-Dosed Intensive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexibly-Dosed Intensive Cognitive Behavioral Therapy (CBT)
Study: 34080309
Drug: Milademetan with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milademetan with strong CYP3A inhibitor (itraconazole or posaconazole)
Study: 34080441
Drug: Acupuncture administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture administered twice per week for 5 weeks, 30 min per session.
Study: 34080708
Drug: Imipenem administered
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem administered by a 4-h infusion of 1 g q6h
Study: 34080708
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage of imipenem
Study: 34080708
Drug: Dosage regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage regimens in patients with renal impairment
Study: 34080792
Drug: Directional atherectomy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directional atherectomy (DA) prior to drug coated balloon (DCB) angioplasty
Study: 34082006
Drug: Sirolimus (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (daily oral for 12 months)
Study: 34082024
Drug: Olaparib +
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib + AZD6738 (ATR inhibitor)
Study: 34082024
Drug: Olaparib +
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib + ceralasertib (ATR inhibitor)
Study: 34082643
Drug: Seasonal influenza
Normalized name: seasonal influenza, intradermal, preservative free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal influenza vaccine (GSK's seasonal inactivated influenza vaccines)
Study: 34083035
Drug: Alkaline comet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkaline comet assay (single cell gel electrophoresis)
Study: 34083035
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to genotoxic agents
Study: 34083209
Drug: New surveillance
Approvals — FDA: no, EMA: no, PMDA: no
Description: New surveillance pathway with multimodal imaging reviewed by trained ophthalmic graders
Study: 34083209
Drug: Seven-field Early
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-field Early Treatment for Diabetic Retinopathy Study (ETDRS) images
Study: 34083232
Drug: PF-06647020 administered
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06647020 administered every 3 weeks at 2.8 mg/kg
Study: 34083232
Drug: PF-06647020 administered
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06647020 administered every 2 weeks at 2.1-3.2 mg/kg
Study: 34083232
Drug: PF-06647020 administered
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06647020 administered every 3 weeks at 0.2-3.7 mg/kg
Study: 34083232
Drug: PF-06647020 administered
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06647020 administered every 3 weeks at highest dose evaluated
Study: 34083236
Drug: CX-2029 at
Normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX-2029 at 4 mg/kg
Study: 34083236
Drug: CX-2029 at
Normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX-2029 at 5 mg/kg
Study: 34083236
Drug: CX-2029 at
Normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX-2029 at 4 mg/kg (expanded cohort)
Study: 34083421
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg intravenously on days 1 and 15, with surgery planned by day 29.
Study: 34083618
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg/day for 15 weeks
Study: 34084608
Drug: Neurotechnology-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotechnology-based therapy (seizure advisory system)
Study: 34085287
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo, no treatment, or conventional therapies)
Study: 34085900
Drug: MenACYW-TT booster
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACYW-TT booster dose
Study: 34086171
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel 80 mg/m² with carboplatin, trastuzumab, and pertuzumab (wPCbTP)
Study: 38112922
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg, twice daily)
Study: 34087943
Drug: Radiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation with concurrent platinum-based chemotherapy
Study: 34087967
Drug: Other (TMG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other (TMG, implant)
Study: 34088733
Drug: Perioperative iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative iron administration
Study: 34089650
Drug: Nusinersen (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nusinersen (6 mg equivalent for cohort 1, 12 mg for cohort 2)
Study: 34089650
Drug: Nusinersen (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nusinersen (12 mg)
Study: 34089751
Drug: Preoperative stereotactic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative stereotactic ablative body radiotherapy (SBRT) as 5 fractions of 7 Gy with dose reduction to 5 fractions of 5 Gy on tumor margins.
Study: 34090525
Drug: Training +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training + implementation enhanced resources (including a champion at each site and monthly peer support consultation calls)
Study: 34090865
Drug: Nanotechnology-based strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanotechnology-based strategies for cancer diagnosis and therapy
Study: 34092158
Drug: Pregabalin pharmacotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin pharmacotherapy, dosage and duration not available